DEFINITIVE CHEMORADIOTHERAPY USING INTENSITY MODULATED RADIOTHERAPY (IMRT) FOR UNRESECTABLE ADVANCED ESOPHAGEAL CANCER

    loading  Checking for direct PDF access through Ovid

Abstract

Background

Recent reported results of definitive chemoradiotherapy have indicated various advantages against unresectable esophageal cancer. We assessed the effect and feasibility of definitive chemoradiotherapy using intensity modulated radiotherapy (IMRT) for unresectable advanced esophageal cancer.

Patient and methods

Sixteen patients with unresectable advanced esophageal cancer were enrolled. Patient received infusion of fluorouracil 500 mg/body/16 h and cisplatin 5 mg/body bouls on days 1 to 5. IMRT was given to 60 Gy in 30 fractions over 6 weeks with concurrent infusion.

Results

The median survival time was 18.3 months, and the 2-/3-year survival rate was 58.0/43.5%. Hematologic toxicity was noted in 13 patients, including one hrade 4 leukopenia. Non-hematologic toxicity was noted in 16 patients, including six grade 2 nausea and one grade 3 esophagitis. No toxicity-related death occurred. The overall response rate of all the 16 registered patients was 93.4% (CR/PR/SD = 9/6/1), and the complete response rate was 56.3%. Recurrence at primary lesion was noted in three patients, and other organ was eight patients.

Conclusion

Despite its relatively constant rate of recurrence at other organ, this definitive chemoradiotheapy using IMRT appears effective and feasible for unresectable advanced esophageal cancer.

Related Topics

    loading  Loading Related Articles